SURGICALLY TARGETED RADIATION THERAPY FOR PATIENTS WITH OPERABLE BRAIN TUMORS
Note: In January 2020, GammaTile Therapy was FDA cleared for the treatment of newly diagnosed malignant brain tumors of all types in addition to the existing clearance for recurrent brain tumors.
Physician and Patient Perspective | July 20, 2020 | Dr. Clark Chen, neurosurgeon at University of Minnesota Health, and Chad, a patient with recurrent glioblastoma treated with GammaTile Therapy
North Carolina CBS | January 24, 2020 | Vidant Health™ and ECU Brody School of Medicine successfully perform first-in-state GammaTile procedure
Cronkite News, Arizona PBS | October 22, 2019 | Battling brain tumors with time-released radiation
Arizona CBS | August 14, 2019 | New therapy to slow down brain tumors forever changes Arizona woman's life
Minnesota CBS | February 14, 2019 | New brain cancer treatment GammaTile Therapy at University of Minnesota with survivor Linda Tinega
Physician Perspective | March 18, 2020 | Dr David McCracken, neurosurgeon at Piedmont Healthcare
Ohio CBS | November 15, 2019 | New brain cancer therapy provides radiation right at tumor site
Physician Perspective | August 14, 2019 | Dr Clark Chen, neurosurgeon at University of Minnesota Health
Introducing GammaTile Therapy
Clinical Presentation | May 1, 2020 | GammaTile Therapy clinical case review with Dr Vincent DiNapoli
Glioma Case Example I
Brain Metastases Case Example
GammaTile Therapy is indicated to deliver radiation therapy for patients with newly diagnosed malignant intracranial neoplasms and recurrent intracranial neoplasms.
For full safety information, refer to the GammaTile Instructions for Use.
Glioma Case Example II
Meningioma Case Example